PriceTargets.com logo

Sabra Healthcare REIT - SBRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $20.78
  • Forecasted Upside: 9.07%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$19.05 As of 12/4/2025 05:00 PM ET
▼ -0.17 (-0.88%)

This chart shows the closing price for SBRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sabra Healthcare REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBRA

Analyst Price Target is $20.78
▲ +9.07% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Sabra Healthcare REIT in the last 3 months. The average price target is $20.78, with a high forecast of $22.00 and a low forecast of $20.00. The average price target represents a 9.07% upside from the last price of $19.05.

This chart shows the closing price for SBRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Sabra Healthcare REIT. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00
11/18/2025UBS GroupInitiated CoverageNeutral$20.00
10/21/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$21.00 ➝ $20.00
10/17/2025National BanksharesSet Target$22.00
10/8/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/1/2025Cantor FitzgeraldInitiated CoverageNeutral$20.00
10/1/2025Cantor FitzgeraldInitiated CoverageNeutral$20.00
9/27/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
9/2/2025Truist FinancialBoost TargetHold ➝ Hold$18.00 ➝ $20.00
8/27/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00
8/25/2025BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$19.00 ➝ $22.00
8/6/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$20.00 ➝ $22.00
6/23/2025ScotiabankBoost TargetSector Perform ➝ Sector Perform$19.00 ➝ $20.00
5/12/2025ScotiabankBoost TargetSector Perform ➝ Sector Perform$18.00 ➝ $19.00
3/18/2025Truist FinancialBoost TargetHold ➝ Hold$17.00 ➝ $18.00
1/17/2025Truist FinancialDowngradeBuy ➝ Hold$18.00 ➝ $17.00
1/7/2025Citizens JmpUpgradeHold ➝ Strong-Buy
1/7/2025JMP SecuritiesUpgradeMarket Perform ➝ Outperform$20.00
12/5/2024MizuhoReiterated RatingOutperform ➝ Neutral$20.00 ➝ $20.00
10/11/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$17.00 ➝ $18.00
10/1/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
9/13/2024CitigroupUpgradeNeutral ➝ Buy$17.00 ➝ $20.00
9/4/2024Truist FinancialBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
8/26/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$15.00 ➝ $17.00
6/27/2024Truist FinancialBoost TargetBuy ➝ Buy$15.00 ➝ $16.00
5/15/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$14.00 ➝ $15.00
2/29/2024WedbushReiterated RatingOutperform$17.00
1/30/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy$21.00
1/3/2024MizuhoBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
11/7/2023Stifel NicolausBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
10/17/2023BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$16.00
10/16/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$13.00 ➝ $15.00
10/10/2023Bank of AmericaUpgradeNeutral ➝ Buy$14.00 ➝ $16.00
10/3/2023WedbushInitiated CoverageOutperform$16.00
9/29/2023Truist FinancialBoost Target$13.00 ➝ $15.00
9/20/2023Jefferies Financial GroupUpgradeHold ➝ Buy$11.00 ➝ $15.00
8/11/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$11.00 ➝ $14.00
7/27/2023Berenberg BankInitiated CoverageHold$13.00
7/14/2023CitigroupBoost TargetNeutral$11.00 ➝ $12.50
5/4/2023Stifel NicolausLower Target$15.00 ➝ $14.00
4/25/2023BarclaysLower Target$15.00 ➝ $13.00
4/19/2023Wells Fargo & CompanyInitiated CoverageUnderweight$11.00
4/12/2023Credit Suisse GroupReiterated RatingNeutral$13.00
3/29/2023Truist FinancialLower TargetBuy$14.00 ➝ $13.00
3/28/2023CitigroupLower TargetNeutral$13.00 ➝ $10.50
12/13/2022JMP SecuritiesDowngradeOutperform ➝ Market Perform
11/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$15.00 ➝ $13.00
10/10/2022Robert W. BairdDowngradeOutperform ➝ Neutral$13.00
8/22/2022CitigroupBoost Target$15.50
8/9/2022BarclaysBoost Target$15.00
6/30/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$15.00 ➝ $14.00
6/3/2022Capital One FinancialInitiated CoverageEqual Weight ➝ Equal Weight$15.50
5/25/2022MizuhoUpgradeNeutral ➝ Buy$16.00 ➝ $15.00
4/18/2022BarclaysDowngradeOverweight ➝ Equal Weight$16.00 ➝ $14.00
4/4/2022Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $15.00
3/11/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$15.00
2/23/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00
2/22/2022BarclaysLower Target$19.00 ➝ $16.00
2/18/2022KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
2/15/2022JMP SecuritiesLower TargetBuy$20.00 ➝ $16.00
2/1/2022Credit Suisse GroupInitiated CoverageNeutral$14.00
1/20/2022MizuhoLower Target$18.00 ➝ $16.00
10/7/2021Robert W. BairdInitiated CoverageOutperform$18.00
9/30/2021Truist FinancialUpgradeHold ➝ Buy$18.00
9/13/2021JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $20.00
5/21/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$20.00 ➝ $21.00
5/9/2021Stifel NicolausUpgradeHold ➝ Buy$17.00 ➝ $21.00
1/13/2021MizuhoDowngradeBuy ➝ Neutral$18.00
1/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$17.00 ➝ $20.00
1/7/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$19.00
12/15/2020Smith Barney CitigroupBoost Target$14.00 ➝ $17.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 36 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 34 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 22 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 32 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 20 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 33 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 33 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sabra Healthcare REIT logo
Sabra Health Care REIT, Inc. engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.
Read More

Today's Range

Now: $19.05
Low: $19.01
High: $19.29

50 Day Range

MA: $18.42
Low: $17.23
High: $19.48

52 Week Range

Now: $19.05
Low: $15.60
High: $19.97

Volume

3,954,911 shs

Average Volume

2,945,704 shs

Market Capitalization

$4.75 billion

P/E Ratio

26.46

Dividend Yield

6.24%

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Healthcare REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Healthcare REIT in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Citizens Jmp, JMP Securities, Mizuho, National Bankshares, Inc., Scotiabank, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for SBRA.

What is the current price target for Sabra Healthcare REIT?

0 Wall Street analysts have set twelve-month price targets for Sabra Healthcare REIT in the last year. Their average twelve-month price target is $20.78, suggesting a possible upside of 9.1%. BMO Capital Markets has the highest price target set, predicting SBRA will reach $22.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $20.00 for Sabra Healthcare REIT in the next year.
View the latest price targets for SBRA.

What is the current consensus analyst rating for Sabra Healthcare REIT?

Sabra Healthcare REIT currently has 6 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SBRA.

What other companies compete with Sabra Healthcare REIT?

Other companies that are similar to Sabra Healthcare REIT include CareTrust REIT, LTC Properties, National Health Investors, Omega Healthcare Investors and Ventas. Learn More about companies similar to Sabra Healthcare REIT.

How do I contact Sabra Healthcare REIT's investor relations team?

Sabra Healthcare REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is (888) 393-8248 and its investor relations email address is [email protected]. The official website for Sabra Healthcare REIT is www.sabrahealth.com. Learn More about contacing Sabra Healthcare REIT investor relations.